RGNT (Regentis Biomaterials) Non Operating Income: $0.23 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RGNT Regentis Biomaterials Ltd RGNT
14 GF Score
Price $1.84
! 2 Warning Signs
View Full Analysis

What is Regentis Biomaterials Non Operating Income?

Regentis Biomaterials RGNT -0.54% 14 Non Operating Income is $0.23 Mil as of Dec. 2025. GuruFocus rates RGNT with a GF Score™ of 14/100. The stock has 2 warning signs investors should review.

Non Operating Income is income or expense that comes from miscellaneous sources. Regentis Biomaterials's Non Operating Income for the six months ended in Dec. 2025 was $0.07 Mil. Its Non Operating Income for the trailing twelve months (TTM) ended in Dec. 2025 was $0.23 Mil.

Regentis Biomaterials Non Operating Income Related Terms

Regentis Biomaterials Non Operating Income Historical Data

* Premium members only.

The historical data trend for Regentis Biomaterials's Non Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regentis Biomaterials Non Operating Income Chart

Regentis Biomaterials Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Non Operating Income
Get a 7-Day Free Trial -0.01 0.36 -0.01 0.56 0.23

Regentis Biomaterials Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Non Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 2.05 0.48 0.08 0.16 0.07
RGNT
14GF Score
Regentis Biomaterials Ltd RGNT
Non Operating Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Regentis Biomaterials Non Operating Income Calculation

Non Operating Income is income or expense that comes from miscellaneous sources.

Non Operating Income for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.23 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Non Operating Income →
What does a Non Operating Income of $0.23 Mil mean?
Regentis Biomaterials (RGNT) has a Non Operating Income of $0.23 Mil as of Dec. 2025. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on Regentis Biomaterials and its competitors.
Is Regentis Biomaterials' Non Operating Income too high?
Regentis Biomaterials' current Non Operating Income is $0.23 Mil. Overall, Regentis Biomaterials has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Regentis Biomaterials' Non Operating Income compare to BNGO and ZJYL?
Regentis Biomaterials' Non Operating Income of $0.23 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Non Operating Income for a Medical Devices & Instruments company?
A good Non Operating Income depends on the Medical Devices & Instruments industry context. However, Non Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Non Operating Income mean?
A high Non Operating Income can signal that a stock is expensive relative to its fundamentals. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on Regentis Biomaterials and its competitors. Regentis Biomaterials's current Non Operating Income is $0.23 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regentis Biomaterials stock overvalued right now?
Regentis Biomaterials (RGNT) has a current Non Operating Income of $0.23 Mil. The current Non Operating Income is $0.23 Mil. Regentis Biomaterials' overall GF Score™ is 14/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Non Operating Income calculated?
Non Operating Income is calculated from a company's financial statements. For Regentis Biomaterials (RGNT), the current Non Operating Income is $0.23 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Regentis Biomaterials Business Description

Address 60, Medinat Hyahudim, Entrance C, Herzlia Pituach, ISR, 4676652
Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing tissue repair solutions that restore health and enhance the quality of life of patients. It is focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Gelrin is a hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen (a biologically inactivated protein that normally has a role in blood clotting). Its product is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage.
14GF Score

Get the complete analysis for RGNT

Non Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.84
Price